Skip to main content
OpenTrials

Clinical trial condition

Paraproteinemias

Explore clinical trials studying Paraproteinemias. Study availability and eligibility vary by location and protocol.

3,004 public trials 571 recruiting studies
Refine in advanced search Browse all conditions

Paraproteinemias trial results

Completed

Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma

NCT00530816

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Mayo Clinic Scottsdale Scottsdale, Arizona, United States
  • Tower Cancer Research Foundation Beverly Hills, California, United States
  • Therapeutic Research Institute of Orange County Laguna Hills, California, United States
  • Rocky Mountain Blood and Marrow Transplant Program Denver, Colorado, United States
View all 30 locations
View Trial Details
Completed

Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function

NCT00721734

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Female Urogenital Diseases, +19 more
Locations
  • University of California- San Francisco San Francisco, California, United States
  • University of Maryland Medical Center Baltimore, Maryland, United States
  • Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States
  • Washington University School of Medicine St Louis, Missouri, United States
View Trial Details
Completed

Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies

NCT00150462

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +20 more
Locations
  • Tower Cancer Research Foundation Beverly Hills, California, United States
  • H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
  • Weil Medical College of Cornell University New York, United States
View Trial Details
Completed

Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed

NCT01194791

Conditions
Amyloidosis, Immune System Diseases, Immunoglobulin Light-chain Amyloidosis, +10 more
Locations
  • Hospital Universitario de Canarias Santa Cruz de Tenerife, Canary Islands, Spain
  • Hospital Germans Trias i Pujol Badalona, Spain
  • Hospital Clínic Barcelona, Spain
  • Hospital de la Santa Creu i Sant Pau Barcelona, Spain
View Trial Details
Completed

Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies

NCT00446342

Conditions
B-Lymphoid Malignancies, Blood Protein Disorders, Cardiovascular Diseases, +29 more
Locations
  • City of Hope Duarte, California, United States
  • Stanford Cancer Center Stanford, California, United States
  • Winship Cancer Institute at Emory University Atlanta, Georgia, United States
  • Greenebaum Cancer Center, University of Maryland Baltimore, Maryland, United States
View Trial Details

Related conditions